Greetings all,

I'm a medical doctor from Vietnam.

I want to discuss to you about my patient. He is 58 years old, he is hospitalize with chronic coughs symptoms. After he was taken chest CT Scaner and biopsy show results Adenocarcinoma. Then he was taken PET/CT scan:

In right lower lobe lung cancer: Size 4cm, Max SUV: 8.

Right adreanl have Max SUV: 7,8

My patient have no EGFR muntation detacted.

I am doing test: ALK, ROS 1, DP L1.

Hi Grace Members,

Grace is happy to present in partnership with the Swedish Cancer Institute " Local Therapies for Metastatic Lung Cancer Who, What, Why, When and How?"  this Saturday, November 10, 2018 | 10:00 am– 1:00 pm Pacific time.   This seminar will be available at no charge in person and as a live webinar.

Progression after 3 1/2 years on Tarceva.  Tissue biopsy showed T790m negative.  Any suggestions/experience on next steps?  Onc suggesting I move to Afatinib or a Opdivo.  PDL1 was tested and is <1%.

Hello friends,

My mom, (aged 77, Adenocarcinoma NSCLC, Stage 4, EGFR and ALK negative)  was diagnosed in 2014, underwent VATS and pleurodesis, followed by 6 cycles of Carboplatin & Alimta, Alimta maintenance, Tarceva (for just a couple of months) and is now on Keytruda for her stage 4, lung cancer treatment.  Her PDL-1 expression was over 70%.

This question is not for a specific patient, it is designed to understand how oncologists would approach this problem. There’s a 50 year old stage IIIb unresectable NSCLC patient with ALK positive FISH biopsy result. PD-L1 25%. ECOG 0-1. Should this patient be treated first line with Chemoradiation+Durvalumab or Alectinib? Would the recommendation be any different with EGFR mutation?